Get the Daily Brief
Latest Biotech News
10x Genomics launches next‑gen Flex — single‑cycle, high‑throughput single‑cell push
10x Genomics unveiled a next‑generation Chromium Flex assay that enables automation‑compatible, plate‑based multiplexing at 384 samples and throughput to profile tens of millions of cells per...
Recursion delivers microglia phenomap — Roche pays $30M milestone
Recursion and Roche/Genentech delivered a whole‑genome microglia phenomap — a dataset of roughly 46 million microglial cell images from massive perturbation screens — triggering a $30 million...
FDA places Intellia phase‑3 CRISPR trials on hold: regulator steps in after liver injury
The FDA has imposed a clinical hold on two Phase 3 trials of Intellia Therapeutics’ CRISPR candidate nexiguran ziclumeran (nex‑z) after a study participant developed a grade‑4 liver event that...
Novo jumps into Metsera bidding war – Pfizer threatens legal fight
Novo Nordisk submitted a surprise counterbid for Metsera, offering $56.50 per share plus contingent value rights that lift the deal to roughly $9 billion in potential equity value. Metsera’s board...
Lilly’s tirzepatide era: sales surge and factory push to secure supply
Eli Lilly reported tirzepatide sales of $10.1 billion in Q3, making the diabetes and obesity drug the world’s top seller for the quarter and prompting the company to raise revenue forecasts....
FDA moves to speed biosimilars: clinical trial bar lowered – policy shift ahead
The FDA published draft guidance proposing to remove routine clinical efficacy study requirements for biosimilars, aligning biosimilar approval pathways more closely with small‑molecule generics....
Thermo Fisher to buy Clario in major market play: $8.9B cash deal
Thermo Fisher Scientific agreed to acquire Clario, a clinical‑trial data and patient‑facing software company, for $8.9 billion in cash plus potential earnouts, a deal that expands Thermo Fisher’s...
Lilly buys Adverum to fast‑track one‑time gene therapy for wet AMD
Eli Lilly agreed to acquire Adverum in a deal focused on ixoberogene soroparvovec (ixo‑vec), a Phase 3 gene therapy candidate for wet age‑related macular degeneration designed as a one‑time...
BridgeBio racks up rare‑disease wins: encaleret Phase 3 success and FDA path eyed
BridgeBio reported Phase 3 success for encaleret in autosomal dominant hypocalcemia type 1 (ADH1), meeting primary and key secondary endpoints with 76% of treated patients achieving serum and...
AI drug discovery deals accelerate: phenomaps and multispecific antibody partnerships
Recursion delivered a genome‑scale microglia phenomap to Roche/Genentech as part of their multi‑year collaboration, triggering a $30 million milestone payment and providing a 46‑million image...
10x Genomics launches next‑gen Flex: massive single‑cell scale meets cost cuts
10x Genomics unveiled the next generation of its Chromium Flex assay, featuring plate‑based, automation‑compatible multiplexing that scales to 384 samples and up to 100 million cells per week....
GSK buys ADC rights, ADC developers present data: pharma doubles down on targeted payloads
GSK struck a headline ADC licensing deal with Syndivia for a preclinical ADC targeting metastatic castration‑resistant prostate cancer, agreeing to pay up to €357 million in upfront and milestone...
FDA halts Intellia’s CRISPR phase-3 trials — liver safety probe
The FDA placed clinical holds on two late-stage Intellia Therapeutics trials testing its in vivo CRISPR therapy for transthyretin amyloidosis (ATTR) after a patient developed serious liver injury....
Novo storms Metsera auction — Pfizer fights back
Novo Nordisk submitted an unsolicited, superior proposal to buy obesity biotech Metsera, challenging Pfizer’s previously announced acquisition and igniting a cross‑border bidding war. Novo’s offer...
GSK takes Syndivia ADC program — $357m upfront for prostate target
GlaxoSmithKline agreed to acquire exclusive rights to Syndivia’s preclinical antibody‑drug conjugate (ADC) targeting metastatic castration‑resistant prostate cancer (mCRPC) in a deal that includes...
BridgeBio posts late‑stage wins — rare disease filings next
BridgeBio announced positive phase 3 results for encaleret in autosomal dominant hypocalcemia type 1 (ADH1), meeting primary and key secondary endpoints with 76% of treated patients achieving...
Lilly posts blowout quarter — builds $1.2B plant for oral GLP‑1
Eli Lilly reported third‑quarter revenue that materially exceeded Street expectations and raised its full‑year outlook, driven by blockbuster performance from its diabetes and weight‑loss...
Thermo Fisher to buy Clario — $8.9B cash deal for trial data software
Thermo Fisher Scientific agreed to acquire Clario, a clinical‑trial data and software company, for approximately $8.9 billion in cash plus earn‑outs, aiming to expand its presence in trial...
FDA proposes cutting clinical‑trial bar for biosimilars — faster copycats
The FDA published draft guidance proposing to eliminate routine comparative clinical efficacy studies for many biosimilar applications, a move intended to shorten development timelines and lower...
Recursion delivers microglia phenomap to Roche — $30m milestone hit
Recursion disclosed delivery of a whole‑genome microglia phenomap to Roche/Genentech under their multi‑year AI discovery collaboration, triggering a $30 million milestone payment. The dataset...